All In Biotech

Drug Trial Radar · NCT02825836

Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects

Phase I/II, First in Human, Dose Escalation Trial of TL 895 Monotherapy in Subjects With Relapsed/Refractory B Cell Malignancies and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Treatment-Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Subjects and Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Small Lymphocytic Lymphoma

Last checked: Nov 19, 2026Latest source record: Jul 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 130 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

130

Planned (sponsor's estimate)

Start

Aug 26, 2016

Primary completion

Dec 1, 2024

Study completion Dec 1, 2025

Sponsor

Lead sponsor
Telios Pharma, Inc.Industry
Sponsor type
Industry
First posted
Jul 7, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this research study is to determine the safety and tolerability of TL-895. There are 2 parts of this study. Part 1 tested increasing doses of TL-895 to identify the recommended safe dose for participants with relapsed/refractory (R/R) B cell malignancies who failed at least 1 but no more than 3 prior therapies. Part 1 of this study is no longer enrolling participants. Arms 1 \& 2 of Part 2 of this study will test different doses of TL-895 in participants with R/R CLL or SLL who have failed at least 1 prior therapy. Arms 1 \& 2 of Part 2 of this study is randomized (like the flip of a coin) to receive a specific treatment dose. If someone participates in arms 1 or 2 of Part 2, the dose they receive will be either 100mg twice a day or 150mg twice a day. Arms 3 and 4 of Part 2 of this study will test the 150mg and 100mg BID dose of TL-895, respectively in treatment naïve participants with CLL/SLL. Arms 5 and 6 of Part 2 will test 150mg TL-895 BID in combination with 240 mg navtemadlin QD in participants with relapsed/refractory and treatment naïve without 17p(del). Arm 7 will test 150mg TL-895 in combination with 240 mg navtemadlin QD in participants with relapsed/refractory CLL/SLL with 17p(del). Every participant in this study will receive TL-895.

Conditions

  • Relapsed/Refractory B Cell Malignancies
  • Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Treatment-Naive B Cell Malignancies

Interventions

  • TL-895Drug

    TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.

  • NavtemadlinDrug

    Navtemadlin is an experimental MDM2 anticancer drug taken by mouth.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 (Dose Escalation): DLTs (Dose Limiting Toxicities) during Cycle 1Time frame: Baseline up to the end of cycle 1 (28 days)
  2. Part 2 (Dose Expansion): Overall Response Rate (ORR)Time frame: Baseline up to end of study (2 years after last patient enrolled)

Locations

17 sites in 7 countries. Site status is shown where the registry gives one.

  • Ohio State University Wexner Medical Center

    Columbus, Ohio

  • The West Clinic

    Germantown, Tennessee

  • Debreceni Egyetem - Borgyógyászati Klinika

    Debrecen, Hungary

  • Eger Markhot Ferenc Kórház

    Eger, Hungary

  • Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi - Istituto di Ematologia e Oncologia Medica

    Bologna, Italy

  • Pratia MCM Krakow

    Krakow, Poland

  • Centrum Onkologii Ziemi Lubelskiej im sw Jana z Dukli Oddzial Hematologiczny

    Lublin, Poland

  • Szpital Wojewódzki

    Opole, Poland

  • Nasz Lekarz Przychodnie Medyczne

    Torun, Poland

  • Examen sp. z o. o.

    Skorzewo, Poznań, Poland

  • Saint Petersburg State Medical University

    Saint Petersburg, Russia

  • Yaroslavl Regional Clinical Hospital

    Yaroslavl, Russia

  • Communal Non-profit Enterprise Regional Center of Oncology

    Kharkiv, Ukraine

  • Kyiv City Clinical Hospital #4

    Kyiv, Ukraine

  • Mykolaiv Regional Clinical Hospital

    Mykolaiv, Ukraine

  • University College London Hospitals - NIHR/Wellcome Trust

    London, United Kingdom

  • Derriford Hospital - Dept of Haematology

    Plymouth, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.